Dermavant is a specialty biopharmaceutical company focused on medical dermatology. Led by its rigorous, science-driven process, Dermavant has rapidly developed an innovative pipeline. This pipeline spans one of the broadest disease state ranges in medical dermatology, including product candidates with multiple indications. Dermavant’s long-range goal is to accelerate delivery of new medicines for patients.
*Completion of transaction with GSK anticipated during the second half of 2018, subject to necessary approvals, anti‐trust, and regulatory clearances.
Investigational drugs. Have not been approved for any indication and subject to health authority approval.
Dermavant Sciences has formed important alliances with companies who share our commitment to develop innovative dermatology drug candidates into medicines that will change the lives of patients with atopic dermatitis and other inflammatory skin diseases.